Name: Women's Health and Menopause: Risk Reduction Strategies (en Inglés)
Price: 266.61 PEN
Availability: InStock
Author: Paoletti, Rodolfo ; Crosignani, P. G. ; Kenemans, P.
ISBN: 9789401063432

portada Women's Health and Menopause: Risk Reduction Strategies (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Paoletti, Rodolfo ; Crosignani, P. G. ; Kenemans, P.

Idioma

Inglés

N° páginas

341

Encuadernación

Tapa Blanda

Dimensiones

23.4 x 15.6 x 2.0 cm

Peso

0.53 kg.

ISBN13

9789401063432

Categorías

Epidemiología y estadística médica
Enfermedades cardiovasculares
Bioquímica

Women's Health and Menopause: Risk Reduction Strategies (en Inglés)

Paoletti, Rodolfo ; Crosignani, P. G. ; Kenemans, P. (Autor) · Springer · Tapa Blanda

Libro Nuevo

S/ 266,61

S/ 533,22

Ahorras: S/ 266,61

50% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 29 de Julio y el Lunes 12 de Agosto.

Lo recibirás en cualquier lugar de Perú entre 2 y 5 días hábiles luego del envío.

Reseña del libro "Women's Health and Menopause: Risk Reduction Strategies (en Inglés)"

Despite its universality in human female aging, the menopause and its biology are not completely understood. New biologic mechanisms by which sex hormones may be detrimental or confer protection are continually being discovered. We are now starting to understand that the role of the estrogen receptor is not identical in all tissues. Important nongenomic effects for sex hormones have also been described. Hormone replacement therapy (HRT) has produced effects on health risks: some are reduced, some are increased, and the rest remain uncertain. HRT is being used by an increasing number of women to alleviate climacteric symptoms in the perimenopausal period and to prevent osteoporosis and cardiovascular disease later. Positive effects on Alzheimer's disease and dementia on the one hand, and an increase in venous thrombosis on the other, are currently being reported by several groups. Both the preventive benefits and the risk of breast cancer seem to be linked to long-term and current use. HRT requires further testing through specific clinical trials, currently underway in the United States, before confident recommendations may be made about the full range of benefits and risks.